| Primary |
| Non-small Cell Lung Cancer |
28.5% |
| Lung Adenocarcinoma |
12.1% |
| Hypertension |
8.2% |
| Pain |
6.3% |
| Analgesic Effect |
5.8% |
| Breast Cancer Metastatic |
4.8% |
| Muscle Spasms |
3.9% |
| Pancreatic Insufficiency |
3.9% |
| Lung Neoplasm Malignant |
3.4% |
| Non-small Cell Lung Cancer Stage Iv |
2.9% |
| Breast Cancer |
2.4% |
| Insomnia |
2.4% |
| Adenosquamous Cell Lung Cancer |
1.9% |
| Angina Pectoris |
1.9% |
| Antacid Therapy |
1.9% |
| Atrial Fibrillation |
1.9% |
| Depression |
1.9% |
| Eczema |
1.9% |
| Lung Adenocarcinoma Stage Iv |
1.9% |
| Neoplasm Malignant |
1.9% |
|
| Interstitial Lung Disease |
13.6% |
| Hepatic Function Abnormal |
8.5% |
| Thrombocytopenia |
6.8% |
| Weight Decreased |
6.8% |
| Hepatotoxicity |
5.1% |
| Myocardial Infarction |
5.1% |
| Pneumonia |
5.1% |
| Renal Failure |
5.1% |
| Respiratory Failure |
5.1% |
| Suffocation Feeling |
5.1% |
| Acute Lung Injury |
3.4% |
| Alanine Aminotransferase Increased |
3.4% |
| Cerebral Ischaemia |
3.4% |
| Death |
3.4% |
| Hepatic Enzyme Increased |
3.4% |
| Leukopenia |
3.4% |
| Propionibacterium Infection |
3.4% |
| Proteinuria |
3.4% |
| Pulmonary Fibrosis |
3.4% |
| Subdural Haemorrhage |
3.4% |
|
| Secondary |
| Ewing's Sarcoma |
11.6% |
| Non-small Cell Lung Cancer |
10.8% |
| Lung Adenocarcinoma |
8.2% |
| Lung Adenocarcinoma Stage Iii |
6.9% |
| Lung Adenocarcinoma Stage Iv |
6.5% |
| Breast Cancer Metastatic |
6.0% |
| Lung Adenocarcinoma Recurrent |
5.6% |
| Chemotherapy Multiple Agents Systemic |
5.2% |
| Metastases To Central Nervous System |
4.7% |
| Chemotherapy |
4.3% |
| Prophylaxis |
4.3% |
| Metastases To Liver |
3.4% |
| Metastatic Renal Cell Carcinoma |
3.4% |
| Angina Pectoris |
3.0% |
| Hypertension |
3.0% |
| Non-small Cell Lung Cancer Stage Iv |
3.0% |
| Neoplasm Malignant |
2.6% |
| Neoplasm Progression |
2.6% |
| Squamous Cell Carcinoma Of Head And Neck |
2.6% |
| Product Used For Unknown Indication |
2.2% |
|
| Transaminases Increased |
11.1% |
| Alanine Aminotransferase Increased |
9.3% |
| Interstitial Lung Disease |
7.4% |
| Vomiting |
7.4% |
| Acute Myeloid Leukaemia |
5.6% |
| Lung Disorder |
5.6% |
| Neutropenia |
5.6% |
| Respiratory Failure |
5.6% |
| Sinus Tachycardia |
5.6% |
| Conjunctivitis |
3.7% |
| Hepatotoxicity |
3.7% |
| Neoplasm |
3.7% |
| Neuropathy Peripheral |
3.7% |
| Pancytopenia |
3.7% |
| Pneumonitis |
3.7% |
| Proteinuria |
3.7% |
| Rash |
3.7% |
| Skin Disorder |
3.7% |
| Anaphylactic Reaction |
1.9% |
| Bone Pain |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
16.0% |
| Lung Adenocarcinoma Stage Iv |
11.5% |
| Lung Adenocarcinoma |
10.7% |
| Pain |
7.6% |
| Drug Use For Unknown Indication |
6.9% |
| Chronic Myeloid Leukaemia |
4.6% |
| Lung Neoplasm Malignant |
4.6% |
| Metastases To Bone |
4.6% |
| Adenocarcinoma |
3.8% |
| Metastases To Liver |
3.8% |
| Gastrointestinal Stromal Tumour |
3.1% |
| Lung Adenocarcinoma Stage Iii |
3.1% |
| Neuralgia |
3.1% |
| Pain In Extremity |
3.1% |
| Bacterial Infection |
2.3% |
| Cytomegalovirus Infection |
2.3% |
| Fatigue |
2.3% |
| Gastritis |
2.3% |
| Hypertension |
2.3% |
| Nausea |
2.3% |
|
| Rash |
16.7% |
| Walking Disability |
11.1% |
| Vomiting |
8.3% |
| Bone Marrow Failure |
5.6% |
| Death |
5.6% |
| Malignant Neoplasm Progression |
5.6% |
| Nephrotic Syndrome |
5.6% |
| Pneumonia |
5.6% |
| Pyrexia |
5.6% |
| Gastrointestinal Haemorrhage |
2.8% |
| Hypoxia |
2.8% |
| Leukoencephalopathy |
2.8% |
| Metastases To Meninges |
2.8% |
| Neoplasm Progression |
2.8% |
| Oxygen Saturation Decreased |
2.8% |
| Pain |
2.8% |
| Pneumothorax |
2.8% |
| Pulmonary Embolism |
2.8% |
| Radial Nerve Palsy |
2.8% |
| Rash Pruritic |
2.8% |
|
| Interacting |
| Lung Adenocarcinoma Stage Iv |
55.6% |
| Neuralgia |
44.4% |
|
| Skin Exfoliation |
66.7% |
| Myelodysplastic Syndrome |
33.3% |
|
